BlueCross BlueShield of Tennessee Medical Policy Manual
IMPORTANT REMINDER
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.
POLICY
INDICATIONS
The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.
FDA-Approved Indications
Compendial Uses
COVERAGE CRITERIA
Adjunctive diagnostic tool for well-differentiated thyroid cancer
Authorization of 1 month may be granted for use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing when ALL of the following criteria are met:
Adjunct treatment for thyroid remnant ablation
Authorization of 1 month may be granted as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants when ALL of the following criteria are met:
Adjunct treatment for multinodular goiter
Authorization of 1 month may be granted when used for adjunct treatment prior to radioiodine treatment of large multinodular goiters.
Adjunct treatment for thyroid cancer
Authorization of 1 month may be granted when used as adjunct treatment for the stimulation of radioiodine uptake in the treatment of patients with differentiated thyroid carcinoma.
Adjunct treatment for brain metastases
Authorization of 1 month may be granted when used as adjunct treatment for the stimulation of radioiodine uptake for the treatment of brain metastases from thyroid cancer.
APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS
BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.
ADDITIONAL INFORMATION
For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).
REFERENCES
ORIGINAL EFFECTIVE DATE: 12/1/2016
MOST RECENT REVIEW DATE: 4/8/2025
ID_CHS
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information